Prolonged evolution of the human B cell response to SARS-CoV-2 infection.


Journal

Science immunology
ISSN: 2470-9468
Titre abrégé: Sci Immunol
Pays: United States
ID NLM: 101688624

Informations de publication

Date de publication:
23 02 2021
Historique:
received: 21 01 2021
accepted: 18 02 2021
entrez: 24 2 2021
pubmed: 25 2 2021
medline: 9 3 2021
Statut: ppublish

Résumé

A comprehensive understanding of the kinetics and evolution of the human B cell response to SARS-CoV-2 infection will facilitate the development of next-generation vaccines and therapies. Here, we longitudinally profiled this response in mild and severe COVID-19 patients over a period of five months. Serum neutralizing antibody (nAb) responses waned rapidly but spike (S)-specific IgG

Identifiants

pubmed: 33622975
pii: 6/56/eabg6916
doi: 10.1126/sciimmunol.abg6916
pmc: PMC8128290
pii:
doi:

Substances chimiques

Antibodies, Monoclonal 0
Antibodies, Neutralizing 0
Antibodies, Viral 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NIAID NIH HHS
ID : R01 AI127521
Pays : United States

Informations de copyright

Copyright © 2021, American Association for the Advancement of Science.

Références

Cell Host Microbe. 2020 Sep 9;28(3):486-496.e6
pubmed: 32738193
Nature. 2020 Jul;583(7815):290-295
pubmed: 32422645
Nat Med. 2021 Apr;27(4):622-625
pubmed: 33654292
PLoS Pathog. 2021 Apr 8;17(4):e1009453
pubmed: 33831132
Annu Rev Immunol. 2017 Apr 26;35:255-284
pubmed: 28142324
Nature. 2021 Apr;592(7855):616-622
pubmed: 33567448
Methods Enzymol. 2002;350:87-96
pubmed: 12073338
Science. 2021 Feb 5;371(6529):
pubmed: 33408181
Cell. 2021 Mar 4;184(5):1201-1213.e14
pubmed: 33571429
Nature. 2019 Feb;566(7744):393-397
pubmed: 30664748
Emerg Infect Dis. 2020 Jun;26(6):1339-1441
pubmed: 32168463
Nature. 2020 Aug;584(7821):437-442
pubmed: 32555388
Science. 2020 Mar 13;367(6483):1260-1263
pubmed: 32075877
Science. 2020 Aug 28;369(6507):1119-1123
pubmed: 32661058
Nat Med. 2020 Sep;26(9):1422-1427
pubmed: 32651581
Cell. 2020 Jul 9;182(1):73-84.e16
pubmed: 32425270
Science. 2021 Feb 19;371(6531):823-829
pubmed: 33495307
Cell. 2019 May 30;177(6):1566-1582.e17
pubmed: 31104840
Cell Host Microbe. 2021 Mar 10;29(3):463-476.e6
pubmed: 33592168
Science. 2020 Aug 7;369(6504):731-736
pubmed: 32540900
Vaccine. 2000 Nov 22;19(7-8):877-85
pubmed: 11115711
Cell. 2021 Jan 7;184(1):169-183.e17
pubmed: 33296701
Cell. 2020 Oct 1;183(1):143-157.e13
pubmed: 32877699
Proc Natl Acad Sci U S A. 2021 Sep 7;118(36):
pubmed: 34417349
Science. 2020 Sep 18;369(6510):1501-1505
pubmed: 32703906
Front Immunol. 2021 Jan 28;11:618685
pubmed: 33584712
Science. 2020 Aug 21;369(6506):956-963
pubmed: 32540903
Cell Host Microbe. 2020 Sep 9;28(3):475-485.e5
pubmed: 32735849
Nat Microbiol. 2020 Apr;5(4):562-569
pubmed: 32094589
Immunity. 2020 Dec 15;53(6):1272-1280.e5
pubmed: 33242394
Nature. 2021 Mar;591(7851):639-644
pubmed: 33461210
Science. 2020 Dec 4;370(6521):1227-1230
pubmed: 33115920
Cell. 2021 Mar 4;184(5):1171-1187.e20
pubmed: 33621484
Nat Rev Immunol. 2014 Jul;14(7):495-504
pubmed: 24948364
Proc Natl Acad Sci U S A. 2020 Mar 24;117(12):6675-6685
pubmed: 32152119
Cell. 2020 Sep 3;182(5):1284-1294.e9
pubmed: 32730807
Nature. 2020 Dec;588(7839):682-687
pubmed: 33045718
Cell. 2020 Aug 20;182(4):828-842.e16
pubmed: 32645326
J Infect Dis. 2021 Feb 3;223(2):197-205
pubmed: 33535236

Auteurs

Mrunal Sakharkar (M)

Adimab LLC, Lebanon, NH 03766, USA.

C Garrett Rappazzo (CG)

Adimab LLC, Lebanon, NH 03766, USA.

Wendy F Wieland-Alter (WF)

Division of Infectious Disease and International Health, Dartmouth Hitchcock Medical Center, Lebanon, NH 03756, USA.

Ching-Lin Hsieh (CL)

Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX 78712, USA.

Daniel Wrapp (D)

Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX 78712, USA.

Emma S Esterman (ES)

Adimab LLC, Lebanon, NH 03766, USA.

Chengzi I Kaku (CI)

Adimab LLC, Lebanon, NH 03766, USA.

Anna Z Wec (AZ)

Adimab LLC, Lebanon, NH 03766, USA.

James C Geoghegan (JC)

Adimab LLC, Lebanon, NH 03766, USA.

Jason S McLellan (JS)

Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX 78712, USA.

Ruth I Connor (RI)

Division of Infectious Disease and International Health, Dartmouth Hitchcock Medical Center, Lebanon, NH 03756, USA.

Peter F Wright (PF)

Division of Infectious Disease and International Health, Dartmouth Hitchcock Medical Center, Lebanon, NH 03756, USA.

Laura M Walker (LM)

Adimab LLC, Lebanon, NH 03766, USA. laura.walker@adimab.com.
Adagio Therapeutics, Inc., Waltham, MA 02451, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH